Mixed-lineage-leukemia (MLL) fusion protein collaborates with Ras to induce acute leukemia through aberrant Hox...

Area of Science:

• Hematology
• Molecular Oncology
• Cancer Biology

Background:

• Mixed-lineage-leukemia (MLL) fusion oncogenes are implicated in infant acute leukemia.
• MLL fusion proteins cooperate with FMS-like receptor tyrosine kinase 3 (FLT3) mutations in leukemogenesis.
• The precise molecular mechanisms underlying this cooperativity remain unclear.

Purpose of the Study:

• To elucidate the molecular network driving MLL-fusion-mediated leukemogenesis.
• To identify key signaling pathways cooperating with MLL fusions in leukemia development.
• To explore potential therapeutic targets for MLL-related leukemia.

Main Methods:

• Utilized murine model systems for MLL-fusion-mediated leukemogenesis.
• Investigated oncogenic transformation in vitro and acute leukemia development in vivo.
• Analyzed the roles of Ras, Raf, and signal transducer and activator of transcription 5 (STAT5) signaling pathways.

Main Results:

• MLL fusion proteins synergistically cooperated with Ras activation (or Raf in vitro) but not STAT5 activation in inducing leukemia.
• HoxA9, a critical MLL-targeted molecule, along with Ras activation (or Raf in vitro), was sufficient to mimic MLL-fusion leukemogenesis.
• Demonstrated that MLL fusion proteins require Ras/Raf pathway activation for leukemic transformation.

Conclusions:

• The molecular crosstalk between Hox gene expression and activated Raf signaling is crucial for MLL-fusion-mediated leukemogenesis.
• These findings highlight the Ras/Raf pathway and Hox molecules as fundamental components in MLL-driven leukemia.
• Suggests potential for novel molecularly targeted therapies against MLL-related leukemias.